(2R)-2-(3,5-dimethoxyphenyl)propanoic acid | 1510836-45-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (2R)-2-(3,5-dimethoxyphenyl)propanoic acid
• 英文别名: (R)-2-(3,5-dimethoxyphenyl)propanoic acid
• CAS: 1510836-45-9
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: DBMMMCYUFZQFIC-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R)-2-(3,5-dimethoxyphenyl)propanoic acid 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 以73%的产率得到(2R)-2-(3,5-dihydroxyphenyl)propanoic acid
  参考文献：
  名称：

  Controlled-Deactivation Cannabinergic Ligands

  摘要：

  We report an approach for obtaining novel cannabinoid analogues with controllable deactivation and improved druggability. Our design involves the incorporation of a metabolically labile ester group at the 2'-position on a series of (-)-Delta(8)-THC analogues. We have sought to introduce benzylic substituents a to the ester group which affect the half-lives of deactivation through enzymatic activity while enhancing the affinities and efficacies of individual ligands for the CB1 and CB2 receptors. The 1'-(S)-methyl, 1'-gem-dimethyl, and 1'-cyclobutyl analogues exhibit remarkably high affinities for both CB receptors. The novel ligands are susceptible to enzymatic hydrolysis by plasma esterases in a controllable manner, while their metabolites are inactive at the CB receptors. In further in vitro and in vivo experiments key analogues were shown to be potent CB1 receptor agonists and to exhibit CBI-mediated hypothermic and analgesic effects.

  DOI：

  10.1021/jm4016075
• 作为产物：
  描述：

  (4R)-4-benzyl-3-[2-(3,5-dimethoxyphenyl)acetyl]oxazolidin-2-one 在 sodium hexamethyldisilazane 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 5.0h， 生成 (2R)-2-(3,5-dimethoxyphenyl)propanoic acid
  参考文献：
  名称：

  Controlled-Deactivation Cannabinergic Ligands

  摘要：

  We report an approach for obtaining novel cannabinoid analogues with controllable deactivation and improved druggability. Our design involves the incorporation of a metabolically labile ester group at the 2'-position on a series of (-)-Delta(8)-THC analogues. We have sought to introduce benzylic substituents a to the ester group which affect the half-lives of deactivation through enzymatic activity while enhancing the affinities and efficacies of individual ligands for the CB1 and CB2 receptors. The 1'-(S)-methyl, 1'-gem-dimethyl, and 1'-cyclobutyl analogues exhibit remarkably high affinities for both CB receptors. The novel ligands are susceptible to enzymatic hydrolysis by plasma esterases in a controllable manner, while their metabolites are inactive at the CB receptors. In further in vitro and in vivo experiments key analogues were shown to be potent CB1 receptor agonists and to exhibit CBI-mediated hypothermic and analgesic effects.

  DOI：

  10.1021/jm4016075

文献信息

• Scalable, Telescoped Hydrogenolysis–Enzymatic Decarboxylation Process for the Asymmetric Synthesis of (<i>R</i>)-α-Heteroaryl Propionic Acids
  作者：Caroline A. Blakemore、Scott P. France、Lacey Samp、Deane M. Nason、Eddie Yang、Roger M. Howard、Karen J. Coffman、Qingyi Yang、Aaron C. Smith、Edelweiss Evrard、Wei Li、Linlin Dai、Lixia Yang、Zhiguang Chen、Qingli Zhang、Fangyan He、Jiesen Zhang

  DOI：10.1021/acs.oprd.0c00397

  日期：2021.3.19

  Enantiopure α-aryl propionic acids are useful building blocks for pharmaceutical research and can be accessed enzymatically using arylmalonate decarboxylases (AMDases) from the corresponding malonic acids. However, the intrinsic instability of malonic acids is a major drawback to this approach in which spontaneous decarboxylation can occur, subsequently eroding enantioselectivity and giving rise to

  对映体纯的α-芳基丙酸是药物研究的有用组成部分，可以使用来自相应丙二酸的芳基丙二酸脱羧酶（AMDases）通过酶途径获得。然而，丙二酸的固有不稳定性是该方法的主要缺点，在该方法中，可能发生自发脱羧，随后侵蚀对映选择性并产生外消旋产物。对于我们希望使用该方法获得的一组N-杂环丙酸，这一点尤其明显。在本文中，我们描述了一种克服自发脱羧问题的方法，在该过程中，相应的二苄基丙二酸酯在双相甲苯-碱性水性缓冲液混合物中进行氢解，并伸缩进入随后的AMDase步骤。
• [EN] SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] COMPOSÉS SPIRO EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA MÉLANOCORTINE 4 ET LEURS UTILISATIONS
  申请人：PFIZER

  公开号：WO2021250541A1

  公开（公告）日：2021-12-16

  Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

  本文描述了公式I的化合物及其药用盐，其中R1、R2、R3、X1、Y1、Y2、Y3、Y4和Y5在此处定义；它们作为MC4R拮抗剂的用途；含有这种化合物和盐的药物组合物；利用这种化合物和盐治疗消瘦症、厌食症或厌食神经症等疾病的用途；以及制备这种化合物和盐的中间体和过程。
• [EN] NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS CANNABINERGIQUES ET LEURS UTILISATIONS
  申请人：UNIV NORTHEASTERN

  公开号：WO2014039042A1

  公开（公告）日：2014-03-13

  Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.

  本发明涉及调节大麻素受体的化合物和组合物、调节大麻素受体的方法以及治疗与调节大麻素受体有关的各种疾病的方法。本公开涉及治疗大麻素依赖、神经病变、炎症、青光眼、神经退行性疾病、运动功能障碍、胃肠道疾病、低温、呕吐、食欲不振或艾滋病相关的厌食症的方法。
• Novel Cannabinergic Compounds and Uses Thereof
  申请人：Northeastern University

  公开号：US20160108016A1

  公开（公告）日：2016-04-21

  Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.

  本发明涉及调节大麻素受体的化合物和组合物、调节大麻素受体的方法以及治疗与调节大麻素受体相关的各种疾病的方法。本公开涉及治疗大麻素依赖、神经病变、炎症、青光眼、神经退行性疾病、运动功能障碍、肠道功能障碍、低体温、呕吐、食欲丧失或艾滋病相关的厌食症的方法。
• METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBOXYLIC ACID ESTER
  申请人：Tokyo University Of Science Educational Foundation Administrative Organization

  公开号：EP2719679A1

  公开（公告）日：2014-04-16

  A method that manufacturers an optically active carboxylic acid ester at high yield and high enantioselectivity is provided. An optically active carboxylic acid ester is manufactured at high yield and high enantioselectivity by reacting a racemic carboxylic acid and a specific alcohol or phenol derivatives in a polar solvent having a dipole moment of 3.0 or higher in the presence of an acid anhydride and an asymmetric catalyst, esterifying one enantiomer of the racemic carboxylic acid at high selectivity, and increasing the amount of esterified carboxylic acid by racemizing the optically active carboxylic acid which is the other enantiomer not used in esterification.

  本发明提供了一种以高产率和高对映选择性生产光学活性羧酸酯的方法。外消旋羧酸和特定的醇或苯酚衍生物在偶极矩为 3.0 或更高的极性溶剂中，在酸酐和不对称催化剂的存在下进行反应，以高选择性酯化外消旋羧酸的一种对映体，并通过消旋光学活性羧酸（即酯化过程中未使用的另一种对映体）来增加酯化羧酸的量。